BioStock: CombiGene comments the final preclinical steps

30 October 2020 - 11:05

The gene therapy company CombiGene, which is developing a new treatment for drug-resistant focal epilepsy, is planning to focus on the final preclinical studies next year and then begin the first study in humans in 2022. BioStock turned to CEO Jan Nilsson for a status update and to talk about what remains to be done before the preclinical program can be terminated.

Read the full interview with CombiGene's CEO Jan Nilsson at

This is a pressrelease from BioStock - Connecting Innovation & Capital

Provided by: Cision
Nasdaq First North GM (Sweden)
CombiGene AB
CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date